NUNZIUM

News That Matters

19/07/2023 ---- 20/07/2023

Alzheimer's disease, a prevalent form of dementia projected to affect an alarming 153 million people globally by 2050, has long been a formidable challenge for the medical community. A new drug, donanemab, developed by Eli Lilly, is now offering a beacon of hope. This antibody medicine, designed to clear protein buildup in Alzheimer's patients' brains, has been found to slow cognitive decline in a global trial.

Donanemab functions similarly to lecanemab, a product of Eisai and Biogen. Both drugs have demonstrated potential in decelerating cognitive decline in Alzheimer's patients. Specifically, donanemab has been found to slow the progression of Alzheimer's disease by approximately a third. This significant finding was determined through a trial involving 1,736 individuals aged 60 to 85 with early-stage Alzheimer's. Over 18 months, half of the participants received a monthly infusion of donanemab, while the other half were administered a placebo. Results published in the Journal of the American Medical Association indicated that after 76 weeks of treatment, donanemab reduced clinical decline by 35.1% in early Alzheimer’s patients with low or medium levels of tau protein.

The trial's participants included Mike Colley, an 80-year-old UK resident, whose experience has ignited optimism among health leaders and Alzheimer's research advocates. Former Prime Minister David Cameron is among those advocating for further research into what he terms a "statin for the brain," and urges government investment in new treatments.

However, the trial also disclosed that brain swelling was a common side effect in up to a third of patients, leading to two fatalities. Coupled with the recent rejection of another Alzheimer's drug, aducanumab, due to safety concerns, experts are urging caution. They warn that donanemab's effects might be modest, and it remains unclear whether the treatment will continue to be effective over a longer period.

Regardless of these challenges, the potential benefits of donanemab are substantial. Approximately 720,000 people in the UK alone could potentially benefit from these emerging Alzheimer's treatments, provided they gain approval. However, the Alzheimer's Society warns that the NHS is not yet equipped to administer these treatments on a large scale.

In terms of cost, lecanemab is currently priced at around $27,500 (£21,000) in the US. The UK's drug watchdog NICE has commenced its appraisal of donanemab for treating mild cognitive impairment or mild dementia due to Alzheimer's disease. Eli Lilly has applied for approval for donanemab in the US and plans to do so in the UK shortly.

In conclusion, donanemab signifies a crucial advancement in the fight against Alzheimer's. Despite the drug's side effects and the challenges associated with large-scale delivery, the potential benefits for millions of people worldwide are undeniable. As Dr Richard Oakley of the Alzheimer’s Society points out, these treatments could mark a turning point in the battle against Alzheimer's, underlining the importance of early and accurate diagnosis for treatment eligibility. As we stand on the brink of this potential medical breakthrough, the world watches in anticipation.

READ MORE

The island nation of Cyprus, renowned for its rich history and stunning beaches, is confronting an unprecedented crisis. A lethal strain of feline coronavirus, known as feline infectious peritonitis (FIP), has claimed nearly 300,000 cats since the beginning of the year. This outbreak, the first of its kind in magnitude, is affecting both stray and domestic cats and raising alarm among experts who warn of a potential significant death toll among the UK's feline population if the virus spreads.

FIP, a fatal inflammatory condition primarily affecting kittens and young cats, is not new. Symptoms include fever, abdominal swelling, energy loss, and occasionally increased aggression. However, the scale of the current outbreak is unparalleled. Dr. Demetris Epaminondas, vice-president of the Pancyprian Veterinary Association, reports a disturbing rise in FIP cases. Given the total feline population in Cyprus is estimated to be around one million, the impact is significant.

Prof. Danièlle Gunn-Moore, a feline medicine specialist at the University of Edinburgh, suggests that the virus may have mutated into a new, more lethal strain. Her team is currently conducting genome sequencing to confirm this. If true, the implications could be far-reaching, with anecdotal evidence pointing to the virus's presence in Turkey, Lebanon, and possibly Israel.

In response to the crisis, Cyprus's local authorities have taken proactive measures, including setting up an advisory team, launching a media awareness campaign, and initiating legislative changes to permit the use of specific drugs for treatment. These drugs, remdesivir and GS-441524, have shown promise in treating FIP, but their high cost and bureaucratic challenges pose significant barriers. The cost of these drugs can range from £2,500 to £6,000 for a cat weighing between 3kg and 4kg, a price beyond many people's means.

With slow government action, some individuals have resorted to purchasing drugs themselves, leading to a black market for cheap, unlicensed drugs. This development is as concerning as the disease itself. Vasiliki Mani, a member of several animal welfare organizations, spent around £3,000 of her savings on treatments for two sick strays, illustrating the desperate measures being taken.

The situation in Cyprus underscores the interconnectedness of our world and the potential indirect impact of global events like the Covid-19 pandemic on the emergence of new disease strains. The Global Center for Health Security (GCHS), a leading U.S. institution for managing high-consequence infections, is closely monitoring this situation among other disease outbreaks worldwide. The hope is that with continued vigilance and research, solutions can be found to protect our feline friends from this lethal disease.

In conclusion, the unprecedented FIP outbreak in Cyprus serves as a stark reminder of life's fragility and the importance of swift action, comprehensive research, and global cooperation in the face of emerging infectious diseases. As we navigate these challenges, we must remember the lessons learned from this feline fiasco and strive to create a safer world for all inhabitants, big and small.

READ MORE